Ruxolitinib Phosphate Global Patent Coverage & Expiry Overview

Track protection status across key markets to assess launch feasibility.

Start your free 7-Day Trial! Book a demo to explore our global patent data.

It is formulated by 2 pharmaceutical companies such as INCYTE CORP, SUN PHARM INDS INC. It is marketed under 3 brand names, including JAKAFI, OPZELURA, LEQSELVI. Available in 7 different strengths, such as EQ 15MG BASE, EQ 5MG BASE, EQ 10MG BASE and others, and administered through 2 routes including TABLET;ORAL, CREAM;TOPICAL.

Strategic Dashboard

info

insightsStrategic Insights

Sourcing & Feasibility

check_circle API availability: autorenew Loading API feasibility...

groups Licensing: 2 potential partners

calendar_todayUS Launch window: autorenew Loading launch window...

timeline Key Patent Barrier & Expiry Timeline

autorenew Loading patent barriers...

factoryGeneric Manufacturer Snapshot

autorenew Loading manufacturers...

gavelRisk & Opportunity Summary

dangerous Risk: autorenew Loading risk analysis...
watch_later Watch: autorenew Loading watch analysis...
rocket_launch Opportunity: autorenew Loading opportunity analysis...
flag
gavel
calendar_today
calendar_today

Access Global Patent Data

Stay ahead with worldwide patent expiry and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patents

Orange Book Drug Approval Timeline

FDA approval history for this ingredient

NDA (New Drug Application) ANDA (Generic Application)

Access Global Exclusivity and Patent Expiry Extensions

Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
✓ Latest exclusivity data and extensions
Unlock Global Access

US Orange Book Patents Expiration Timeline

Key expiration dates for US patents covering this ingredient

View Global Patents Expiration Timeline

Stay ahead with worldwide patent expiry insights, market data, and research updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patent Timeline

Orange Book Drug Strengths

Latest drug strengths approved by FDA

Strength Route of Administration Companies Latest Approval Date

Orange Book Patents

Patents approved by the FDA for the ingredient

Patent Number Publication Date Legal Status Patent Expiry Date
{"application_id":"54986","ingredient":"RUXOLITINIB PHOSPHATE","trade_name":"OPZELURA","family_id":"9df4d8c144f64728bf9b","publication_number":"US9974790B2","cleaned_patent_number":"9974790","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2027-06-12","publication_date":"2018-05-22","legal_status":"Granted"} US9974790B2 22 May, 2018 Granted 12 Jun, 2027
{"application_id":"54988","ingredient":"RUXOLITINIB PHOSPHATE","trade_name":"OPZELURA","family_id":"9df4d8c144f64728bf9b","publication_number":"US10639310B2","cleaned_patent_number":"10639310","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2027-06-12","publication_date":"2020-05-05","legal_status":"Granted"} US10639310B2 05 May, 2020 Granted 12 Jun, 2027
{"application_id":"54985","ingredient":"RUXOLITINIB PHOSPHATE","trade_name":"JAKAFI","family_id":"9df4d8c144f64728bf9b","publication_number":"US9814722B2","cleaned_patent_number":"9814722","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2027-06-12","publication_date":"2017-11-14","legal_status":"Granted"} US9814722B2 14 Nov, 2017 Granted 12 Jun, 2027
{"application_id":"54842","ingredient":"RUXOLITINIB PHOSPHATE","trade_name":"JAKAFI","family_id":"9df4d8c144f64728bf9b","publication_number":"US9079912B2","cleaned_patent_number":"9079912","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2027-06-12","publication_date":"2015-07-14","legal_status":"Granted"} US9079912B2 14 Jul, 2015 Granted 12 Jun, 2027
{"application_id":"54978","ingredient":"RUXOLITINIB PHOSPHATE","trade_name":"JAKAFI","family_id":"9df4d8c144f64728bf9b","publication_number":"US8415362B2","cleaned_patent_number":"8415362","drug_product_flag":"-, Y","drug_substance_flag":"-, Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2028-06-24","publication_date":"2013-04-09","legal_status":"Granted"} US8415362B2 09 Apr, 2013 Granted 24 Jun, 2028
{"application_id":"54977","ingredient":"RUXOLITINIB PHOSPHATE","trade_name":"JAKAFI","family_id":"9df4d8c144f64728bf9b","publication_number":"US7598257B2","cleaned_patent_number":"7598257","drug_product_flag":"-, Y","drug_substance_flag":"-, Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2028-06-24","publication_date":"2009-10-06","legal_status":"Granted"} US7598257B2 06 Oct, 2009 Granted 24 Jun, 2028
{"application_id":"121831","ingredient":"RUXOLITINIB PHOSPHATE","trade_name":"JAKAFI","family_id":"951e8a637b6a4603a869","publication_number":"US10016429B2","cleaned_patent_number":"10016429","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2028-12-12","publication_date":"2018-07-10","legal_status":"Granted"} US10016429B2 10 Jul, 2018 Granted 12 Dec, 2028
{"application_id":"121834","ingredient":"RUXOLITINIB PHOSPHATE","trade_name":"OPZELURA","family_id":"951e8a637b6a4603a869","publication_number":"US10610530B2","cleaned_patent_number":"10610530","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2028-12-12","publication_date":"2020-04-07","legal_status":"Granted"} US10610530B2 07 Apr, 2020 Granted 12 Dec, 2028
{"application_id":"55078","ingredient":"RUXOLITINIB PHOSPHATE","trade_name":"JAKAFI","family_id":"951e8a637b6a4603a869","publication_number":"US8722693B2","cleaned_patent_number":"8722693","drug_product_flag":"-, Y","drug_substance_flag":"-, Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2028-12-12","publication_date":"2014-05-13","legal_status":"Patented case"} US8722693B2 13 May, 2014 Patented case 12 Dec, 2028
{"application_id":"121837","ingredient":"RUXOLITINIB PHOSPHATE","trade_name":"JAKAFI","family_id":"951e8a637b6a4603a869","publication_number":"US8822481B1","cleaned_patent_number":"8822481","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2028-12-12","publication_date":"2014-09-02","legal_status":"Granted"} US8822481B2 02 Sep, 2014 Granted 12 Dec, 2028
{"application_id":"55080","ingredient":"RUXOLITINIB PHOSPHATE","trade_name":"JAKAFI","family_id":"951e8a637b6a4603a869","publication_number":"US8829013B1","cleaned_patent_number":"8829013","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2028-12-12","publication_date":"2014-09-09","legal_status":"Patented case"} US8829013B2 09 Sep, 2014 Patented case 12 Dec, 2028
{"application_id":"54838","ingredient":"RUXOLITINIB PHOSPHATE","trade_name":"OPZELURA","family_id":"4b939a12da46466e835c","publication_number":"US11571425B2","cleaned_patent_number":"11571425","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-05-20","publication_date":"2023-02-07","legal_status":"Granted"} US11571425B2 Formulation 07 Feb, 2023 Granted 20 May, 2031
{"application_id":"164411","ingredient":"RUXOLITINIB PHOSPHATE","trade_name":"OPZELURA","family_id":"4b939a12da46466e835c","publication_number":"US12226419B2","cleaned_patent_number":"12226419","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-05-20","publication_date":"2025-02-18","legal_status":"Granted"} US12226419B2 Formulation 18 Feb, 2025 Granted 20 May, 2031
{"application_id":"111299","ingredient":"RUXOLITINIB PHOSPHATE","trade_name":"OPZELURA","family_id":"4b939a12da46466e835c","publication_number":"US11590136B2","cleaned_patent_number":"11590136","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-05-20","publication_date":"2023-02-28","legal_status":"Granted"} US11590136B2 28 Feb, 2023 Granted 20 May, 2031
{"application_id":"54834","ingredient":"RUXOLITINIB PHOSPHATE","trade_name":"OPZELURA","family_id":"4b939a12da46466e835c","publication_number":"US10869870B2","cleaned_patent_number":"10869870","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-11-20","publication_date":"2020-12-22","legal_status":"Granted"} US10869870B2 22 Dec, 2020 Granted 20 Nov, 2031
{"application_id":"54833","ingredient":"RUXOLITINIB PHOSPHATE","trade_name":"OPZELURA","family_id":"4b939a12da46466e835c","publication_number":"US10758543B2","cleaned_patent_number":"10758543","drug_product_flag":"-, Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-11-20","publication_date":"2020-09-01","legal_status":"Granted"} US10758543B2 01 Sep, 2020 Granted 20 Nov, 2031
{"application_id":"54780","ingredient":"RUXOLITINIB PHOSPHATE","trade_name":"OPZELURA","family_id":"4b939a12da46466e835c","publication_number":"US11219624B2","cleaned_patent_number":"11219624","drug_product_flag":"-, Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-11-20","publication_date":"2022-01-11","legal_status":"Granted"} US11219624B2 11 Jan, 2022 Granted 20 Nov, 2031
{"application_id":"130738","ingredient":"DEURUXOLITINIB PHOSPHATE","trade_name":"LEQSELVI","family_id":"","publication_number":"US12076323B2","cleaned_patent_number":"12076323","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2037-05-04","publication_date":"2024-09-03","legal_status":"Granted"} US12076323B2 03 Sep, 2024 Granted 04 May, 2037
{"application_id":"130737","ingredient":"DEURUXOLITINIB PHOSPHATE","trade_name":"LEQSELVI","family_id":"","publication_number":"US10561659B2","cleaned_patent_number":"10561659","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2037-05-04","publication_date":"2020-02-18","legal_status":"Granted"} US10561659B2 18 Feb, 2020 Granted 04 May, 2037
{"application_id":"111714","ingredient":"RUXOLITINIB PHOSPHATE","trade_name":"OPZELURA","family_id":"b04bc462e5a5487dab14","publication_number":"US11590138B2","cleaned_patent_number":"11590138","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2040-06-10","publication_date":"2023-02-28","legal_status":"Granted"} US11590138B2 28 Feb, 2023 Granted 10 Jun, 2040
{"application_id":"164410","ingredient":"RUXOLITINIB PHOSPHATE","trade_name":"OPZELURA","family_id":"b04bc462e5a5487dab14","publication_number":"US12233067B2","cleaned_patent_number":"12233067","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2040-07-28","publication_date":"2025-02-25","legal_status":"Granted"} US12233067B2 25 Feb, 2025 Granted 28 Jul, 2040
{"application_id":"110403","ingredient":"RUXOLITINIB PHOSPHATE","trade_name":"OPZELURA","family_id":"9c8d08b26ccf44b88e3a","publication_number":"US11590137B2","cleaned_patent_number":"11590137","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2040-09-04","publication_date":"2023-02-28","legal_status":"Granted"} US11590137B2 28 Feb, 2023 Granted 04 Sep, 2040
{"application_id":"110395","ingredient":"RUXOLITINIB PHOSPHATE","trade_name":"OPZELURA","family_id":"eacae91194674307a4fa","publication_number":"US11510923B2","cleaned_patent_number":"11510923","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2040-09-04","publication_date":"2022-11-29","legal_status":"Granted"} US11510923B2 29 Nov, 2022 Granted 04 Sep, 2040
{"application_id":"111722","ingredient":"RUXOLITINIB PHOSPHATE","trade_name":"OPZELURA","family_id":"b04bc462e5a5487dab14","publication_number":"US11602536B2","cleaned_patent_number":"11602536","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2041-05-05","publication_date":"2023-03-14","legal_status":"Granted"} US11602536B2 14 Mar, 2023 Granted 05 May, 2041
{"application_id":"130736","ingredient":"DEURUXOLITINIB PHOSPHATE","trade_name":"LEQSELVI","family_id":"","publication_number":"US11919907B2","cleaned_patent_number":"11919907","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2041-05-21","publication_date":"2024-03-05","legal_status":"Granted"} US11919907B2 Formulation 05 Mar, 2024 Granted 21 May, 2041
{"application_id":"242158","ingredient":"DEURUXOLITINIB PHOSPHATE","trade_name":"LEQSELVI","family_id":"","publication_number":"US12285432B2","cleaned_patent_number":"12285432","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2042-08-11","publication_date":"2025-04-29","legal_status":"Granted"} US12285432B2 29 Apr, 2025 Granted 11 Aug, 2042
{"application_id":"164479","ingredient":"DEURUXOLITINIB PHOSPHATE","trade_name":"LEQSELVI","family_id":"","publication_number":"US12247034B1","cleaned_patent_number":"12247034","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2044-05-10","publication_date":"2025-03-11","legal_status":"Granted"} US12247034B2 Molecular Formulation 11 Mar, 2025 Granted 10 May, 2044

Recent Clinical Trials

Latest clinical trials and research studies for this ingredient

NCT ID Title Status Phase Conditions Start Date Completion Date

API Suppliers/Manufacturer (Branded/Generic companies)

Manufacturing Locations

View Complete Supplier List

Unlock access to all suppliers of Ruxolitinib Phosphate

✓ Access a comprehensive list of global suppliers
✓ Get information on each supplier
Unlock Suppliers

Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.

GreyB © 2025 Elixir. All rights reserved.